Longitudinal studies demonstrate that decrease in adipocyte size that accompanies weight loss associates with improved obesity-related disease endpoints in some (Table 1, tier 2), though not all studies (48, 49), and pioglitazone treatment actually induced improved insulin sensitivity that associated with increase, not decrease, in adipocyte size (50). The gene discussed is INS; the disease is Obesity.